GlassScriptPhysician profile
Morgan Mackey
NPI 1699087809
$4,016.77
in general payments reported to CMS, 2019-2025
26 companies · $467 in 2025
The $467 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $705 · 2020: $537 · 2021: $1,263 · 2022: $443 · 2023: $269 · 2024: $334 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $984 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $984.36 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,282.17 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $275.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $254.26 | 2019-2025 | |
| Pfizer INC. | $249.18 | 2019-2024 | |
| Janssen Biotech, INC. | $245.40 | 2019-2025 | Tremfya, Remicade, Stelara |
| Hologic Sales and Service, LLC | $215.35 | 2024-2025 | Novasure, Myosure Tissue Removal Device, Omni Hysteroscope |
| Genzyme Corporation | $185.54 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $173.32 | 2021-2024 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $133.39 | 2019-2021 | |
| Coopersurgical, INC. | $115.54 | 2022 | |
| Ucb, INC. | $107.42 | 2019-2025 | Bimzelx |
| Leo Pharma INC. | $95.42 | 2021 | |
| Amgen INC. | $92.82 | 2020-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $82.89 | 2020-2022 | |
| Vyne Pharmaceuticals INC. | $71.01 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $64.12 | 2020-2022 | |
| Misonix INC | $63.35 | 2021 | |
| Lilly USA, LLC | $62.87 | 2019-2025 | Ebglyss, Taltz |
| Arcutis Biotherapeutics, INC. | $58.73 | 2024-2025 | Zoryve |
| Galderma Laboratories, L.P. | $47.86 | 2021-2023 | |
| Dermira, INC. | $36.15 | 2019-2021 | |
| Kyowa Kirin, INC. | $35.23 | 2020-2021 | |
| Allergan, INC. | $21.42 | 2021 | |
| Tactile Systems Technology INC | $19.04 | 2024 | Entre Plus, Flexitouch Plus |
| Almirall LLC | $15.55 | 2022 | |
| Merck Sharp & Dohme LLC | $13.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Mackey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.